Diagnostic Consultative Centre Ascendent OOD
- Address
- lock Available on a paid plan
Diagnostic Consultative Centre Ascendent OOD
Diagnostic Consultative Centre Ascendent OOD is a comprehensive clinical research facility specializing in cardiovascular disease and metabolic disorder trials. The center demonstrates particular expertise in conducting large-scale Phase 3 studies evaluating novel therapeutic interventions for high-risk patient populations, with a strong focus on atherosclerotic cardiovascular disease prevention and lipid metabolism disorders.
- Cardiovascular disease prevention and major adverse cardiovascular events (MACE) studies, including trials for atherosclerotic cardiovascular disease, atrial fibrillation, and stroke prevention
- Metabolic disorders research, including severe hypertriglyceridemia and obesity management
- Rheumatologic conditions, particularly axial spondyloarthritis and inflammatory disorders
- Women's health research, focusing on endometriosis-related pain management
The center has extensive experience with innovative therapeutic modalities including anticoagulation therapies, lipid-modifying treatments, and novel biologics. Their research portfolio includes evaluation of cutting-edge medications such as Factor XIa inhibitors for thromboembolism prevention, CETP inhibitors for cardiovascular protection, and FGF21 analogs for triglyceride management. The facility's capabilities extend to complex cardiovascular safety studies in metabolic populations and primary prevention trials, positioning them as a key contributor to advancing evidence-based medicine across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 79 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 78 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Pfizer Inc.3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic Consultative Centre Ascendent OOD
lock Showing 1 of 56 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis | Novartis Pharma AG | Phase II | Not Yet Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 79 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 4 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.